Join
Live feed
·
PRReleasevia Quantisnow
RAPT Therapeutics Inc. logo

RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

ByQuantisnow·Wall Street's wire, on your screen.
RAPT· RAPT Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RAPT (RAPT Therapeutics Inc.) and more on Quantisnow.